TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Normalization of ALT at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodic memory encoding impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immediate ordered recall of whole numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean vecuronium demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stable relaxation of 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean offset from the target value of 90% blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mental health outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ca(2+) influx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health Status Index improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systolic/diastolic BP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of total clinical events in perioperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative rebleeding free rate within 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of missing consecutive data collection visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean frequency of applications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of each application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from recurrences of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of venoconstrictor responses to Ang II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ED80 for phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increase in plasma levels of sulfated DHEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in bioavailable testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in BMD at the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Putamen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total assisted recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in IL-6 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in THQ scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Craving for opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance use severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of desipramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC ratio of 2-OH-desipramine/desipramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatine Kinase (CK) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diarrhea among children under the age of five
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious infection
Endpoint domain: Adverse events/effects
Primary endpoint: Demyelination
Endpoint domain: Adverse events/effects
Primary endpoint: Increased cross-sectional area of the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of patients achieving HbA1c <6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower body endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation with clinical UPDRS scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of cardiac complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of using 360QS in childhood obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder joint position sense (JPS) error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulatory T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cat dander-specific IgG(4) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical cure of mycoplasma or chlamydia infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed defervescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum phosphate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total cumulative stool output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: rate of stool output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tinnitus perception reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Atrial Fibrillation (AF)
Endpoint domain: Adverse events/effects
Primary endpoint: Total late complications
Endpoint domain: Adverse events/effects
Primary endpoint: Adjusted mean flow rates (QbEff)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Role limitations due to emotional problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: EQ-5D index value
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PImax values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal velocity (Vm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in soluble intercellular adhesion molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average time-trial power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sexually transmitted infections (STIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Risk-taking behaviors
Endpoint domain: Life impact
Primary endpoint: venous and arterial thromboembolism (VTE) incidence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically meaningful outcome after CIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma increases in prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hormonal responses to follicular puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean antibody concentrations to Hib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of ulcers (≥3-mm diameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of larger ulcers (≥5-mm diameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of dyspepsia, abdominal pain, gastro‐oesophageal reflux, and nausea
Endpoint domain: Adverse events/effects
Primary endpoint: FFA levels suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: recurrence of cerebral infarction
Endpoint domain: Mortality/survival
Primary endpoint: lumbar spine BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total hip BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of C‐telopeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of dyspepsia
Endpoint domain: Adverse events/effects
Primary endpoint: Complete control of anorexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Control rate of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of time spent active
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: willingness to undergo future unsedated colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: nonsurgical resolution of vitreomacular adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exhaled nitric oxide (eNO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean bioavailability following intranasal administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak plasma concentration of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of intranasal administration
Endpoint domain: Adverse events/effects
Primary endpoint: Overall survival associated with high circulating NK cell counts
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival associated with high CD8+ TIL counts
Endpoint domain: Mortality/survival
Primary endpoint: Therapeutic glycemic response (HbA1c <7.0%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease of active clinical symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapy failure
Endpoint domain: Adverse events/effects
Primary endpoint: 10-year KM survival estimate of ZC FDPs
Endpoint domain: Mortality/survival
Primary endpoint: 10-year KM survival estimate of MC FDPs
Endpoint domain: Mortality/survival
Primary endpoint: Rate of framework fracture, de-bonding, major fractures of the veneering ceramic and poor marginal adaption in ZC FDPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of grade >1 peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: rate of dose reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Pain reduction (SPID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of peripheral plasma hyaluronan and syndecan‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oligoadenylate synthetase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum neopterin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta(2)-microglobulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control (FBS, HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Emotional wellbeing (HARS, HDRS scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completeness of medication reviews
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intact collagen remaining in mineralized dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: canal wall erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication wastage reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to full recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BOLD fMRI signal magnitude change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception change (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate after 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Mean time-to-failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of biliary cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in epilepsy knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improved confidence in discussing epilepsy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in maladaptive behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social skills improvement on Vineland Adaptive Behavior Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ABC Irritability subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental 8.5 days without symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DLCO measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival free of noncardiac or perioperative deaths
Endpoint domain: Mortality/survival
Primary endpoint: PYY levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum total cholesterol (TC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum triglycerides (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to TOF ratio of ≥ 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bronchospasm
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of improvement in aortic VTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucose‐plus‐insulin‐stimulated thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total energy expenditures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total SPADI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seven-day EOT-PP abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-day EOT-PP abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first cigarette during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of re-operation at 10 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distalization of the first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distal tipping of the first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anchorage loss at the front teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient compliance rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of FDG-PET for detecting recurrent or persistent NPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of FDG-PET for detecting recurrent or persistent NPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of FDG-PET for detecting recurrent or persistent NPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new or progressed fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Twenty-three-hour RER adjusted for sleeping RER
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients' experiences of MS relapse management
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: all vascular events
Endpoint domain: Mortality/survival
Primary endpoint: overall survival after R0 resection
Endpoint domain: Mortality/survival
Primary endpoint: distant metastasis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Fullness at 1 h post-meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative reduction of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant improvement in radial and palmar abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: significant gain in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Transitioning from light to heavy drinking state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metacarpal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effectiveness of multifactorial fall prevention program in cognitive impairment
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of multifactorial fall prevention program in history of falls
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of multifactorial fall prevention program in urinary incontinence
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of multifactorial fall prevention program in mood problems
Endpoint domain: Mortality/survival
Primary endpoint: Healing time of stage II ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of NEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma levels of endothelin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death or BPD at 36 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Ventilator support at 36 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of healed patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month retention rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of pops per manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of a single audible pop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent condom use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PDAI (Pouchitis Disease Activity Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of IL‐1, IL‐6 and TNF‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: baseline HVPG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: meal-stimulated HVPG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: circadian PVF reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: time to virological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvements in virological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvements in immunological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enflurane requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total anaesthetic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median EEG frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator weaning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of high man-machine confrontation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes